stoxline Quote Chart Rank Option Currency Glossary
  
Iterum Therapeutics plc (ITRM)
1.41  0.11 (8.46%)    02-12 19:59
Open: 1.31
High: 1.42
Volume: 389,368
  
Pre. Close: 1.3
Low: 1.29
Market Cap: 49(M)
Technical analysis
2025-02-12 4:45:48 PM
Short term     
Mid term     
Targets 6-month :  1.91 1-year :  2.17
Resists First :  1.63 Second :  1.86
Pivot price 1.48
Supports First :  1.27 Second :  1.06
MAs MA(5) :  1.38 MA(20) :  1.49
MA(100) :  1.53 MA(250) :  1.42
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  16.3 D(3) :  12.5
RSI RSI(14): 40.8
52-week High :  3.01 Low :  0.8
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ITRM ] has closed above bottom band by 27.0%. Bollinger Bands are 51.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.42 - 1.43 1.43 - 1.44
Low: 1.27 - 1.28 1.28 - 1.29
Close: 1.39 - 1.41 1.41 - 1.42
Company Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Headline News

Sat, 08 Feb 2025
Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance

Fri, 07 Feb 2025
Iterum Therapeutics Highlights FDA Approval and Financial Progress - TipRanks

Fri, 07 Feb 2025
Earnings call transcript: Iterum Therapeutics reports Q4 2024 results and stock surges - MSN

Fri, 07 Feb 2025
Iterum Therapeutics PLC Files For Mixed Shelf Of Up To $150 Million -February 07, 2025 at 04:42 pm EST - Marketscreener.com

Fri, 07 Feb 2025
Iterum Therapeutics PLC reports results for the quarter ended December 31 - Earnings Summary - TradingView

Fri, 07 Feb 2025
Iterum Therapeutics plc (ITRM) reports earnings - Quartz

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 28 (M)
Shares Float 22 (M)
Held by Insiders 1.8 (%)
Held by Institutions 8.9 (%)
Shares Short 2,530 (K)
Shares Short P.Month 215 (K)
Stock Financials
EPS -1.76
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.47
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -73.4 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.36
Qtrly Earnings Growth 0 %
Operating Cash Flow -42 (M)
Levered Free Cash Flow -28 (M)
Stock Valuations
PE Ratio -0.81
PEG Ratio 0
Price to Book value -3
Price to Sales 0
Price to Cash Flow -0.93
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android